CalciMedica (CALC) Insider Robert Wilson Buys $946K of Stock

Robert Wilson Leads a Wave of Insider Buying in CalciMedica, Inc. CALC Stock

Robert Wilson made a large purchase of CalciMedica, Inc. (NasdaqCM: CALC) shares on June 25, 2026, acquiring 1,182,621 shares. The transaction took place at a price of $0.80 per share, bringing the total value of the purchase to $946,096.80. This filing shows a major commitment from Wilson, coming on the exact same day that several other key leaders at the company also added to their personal holdings.

Inside the Executive Buying Spree at CalciMedica, Inc. CALC Stock

Wilson wasn't the only leader stepping up to buy shares on June 25, 2026. Chief Executive Officer Rachel Leheny picked up 186,729 shares at $0.80 each for a total value of $149,383.20. Chief Business Officer Eric Roberts also purchased 186,729 shares at the same price, worth $149,383.20. Meanwhile, Fred Middleton acquired 248,972 shares valued at $199,177.60, and Chief Medical Officer Sudarshan Hebbar bought 124,486 shares for $99,588.80. None of these transactions were carried out under a pre-arranged trading plan.

CalciMedica, Inc. CALC Stock Context and Trading Levels

The shares recently changed hands at $0.99, staying close to the purchase price paid by the executive team. The equity has faced downward pressure over the past year, trading far beneath its 52-week high of $36.00 and just above its 52-week low of $1.86. The spot price also sits under its 50-day moving average of $3.03 and its 200-day moving average of $7.75.

Guggenheim Analyst Coverage and Targets

Wall Street firms continue to evaluate the clinical-stage biotech company's prospects. On August 20, 2026, Guggenheim initiated coverage on the stock with a Buy rating and set a price target of $9.00. Overall, three analyst opinions contribute to a mean price target of $50.00, reflecting a wide range of expectations between a low of $30.00 and a high of $75.00.

What CalciMedica, Inc. Does

Based in La Jolla, California, CalciMedica, Inc. operates as a clinical-stage biopharmaceutical firm focused on treatments for illnesses tied to inflammatory processes, immunologic conditions, and direct cellular damage. Its lead candidate, Auxora, is designed to treat acute pancreatitis, severe pneumonia, and acute kidney injury by inhibiting calcium release-activated calcium channels.

Looking Ahead for CalciMedica, Inc. CALC Stock

Investors will watch to see if leadership continues accumulating shares in future regulatory filings and how upcoming clinical trial updates progress. The company's next financial results are anticipated around August 11, 2025, providing another look at its balance sheet and operational runway.